Insulin degludec
| Clinical data | |
|---|---|
| Trade names | Tresiba |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a615055 |
| License data | |
| Pregnancy category |
|
| Routes of administration | Subcutaneous |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Onset of action | 30–90 minutes |
| Duration of action | ≤ 42 hours |
| Identifiers | |
| |
| CAS Number | |
| PubChem SID | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C274H411N65O81S6 |
| Molar mass | 6104.04 g·mol−1 |
| (what is this?) (verify) | |
Insulin degludec (INN/USAN) is an ultralong-acting basal insulin analogue that was developed by Novo Nordisk under the brand name Tresiba. It is administered via subcutaneous injection to help control the blood sugar level of those with diabetes. It has a duration of action that lasts up to 42 hours (compared to 18 to 26 hours provided by other marketed long-acting insulins such as insulin glargine and insulin detemir), making it a once-daily basal insulin, that is one that provides a base insulin level, as opposed to the fast- and short-acting bolus insulins.
Insulin degludec is a modified insulin that has one single amino acid deleted in comparison to human insulin, and is conjugated to hexadecanedioic acid via gamma-L-glutamyl spacer at the amino acid lysine at position B29.
It is included on the World Health Organization's List of Essential Medicines as an equivalent to insulin glargine. In 2022, it was the 138th most commonly prescribed medication in the United States, with more than 4 million prescriptions.